^
    Back
    Association details:
    Biomarker:SPI1 overexpression
    Cancer:Clear Cell Renal Cell Carcinoma
    Drug Class:Immunotherapy
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    Discov Oncol
    Title:

    SPI1 is a prognostic biomarker of immune infiltration and immunotherapy efficacy in clear cell renal cell carcinoma

    Published date:
    12/07/2022
    Excerpt:
    Non-responders to immunotherapy against ccRCC were more likely to express higher SPI1 levels than responders.
    DOI:
    10.1007/s12672-022-00592-0